Journal article
Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: A randomized trial of IV iron in critical illness
The IRONMAN Investigators, E Litton, S Baker, WN Erber, S Farmer, J Ferrier, C French, J Gummer, D Hawkins, A Higgins, A Hofmann, B De Keulenaer, J McMorrow, JK Olynyk, T Richards, S Towler, R Trengove, S Webb, The Australian
Intensive Care Medicine | SPRINGER | Published : 2016
Abstract
Purpose: Both anaemia and allogenic red blood cell transfusion are common and potentially harmful in patients admitted to the intensive care unit. Whilst intravenous iron may decrease anaemia and RBC transfusion requirement, the safety and efficacy of administering iron intravenously to critically ill patients is uncertain. Methods: The multicentre, randomized, placebo-controlled, blinded Intravenous Iron or Placebo for Anaemia in Intensive Care (IRONMAN) study was designed to test the hypothesis that, in anaemic critically ill patients admitted to the intensive care unit, early administration of intravenous iron, compared with placebo, reduces allogeneic red blood cell transfusion during ho..
View full abstractGrants
Funding Acknowledgements
Dr. Richards reports grants from the UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA), the Australian National Health and Medical Research Council (NHMRC) and the UK National Institute of Academic Anaesthesia (NIAA)/British Journal of Anaesthesia (BJA)/Association of Cardiothoracic Anaesthetists (ACTA)/Vascular Anaesthesia Society of Great Britain and Ireland (VASGBI); grants, personal fees and non-financial support from Pharmocosmos, Vifor Pharma, Acelity and the Stroke Association; grants from Mason Medical Research Foundation and University College Hospital (UCH) League of Friends; grants and non-financial support from Libresse/Bodyform, outside the submitted work. TR is a regular speaker at national and international conferences on anaemia, blood transfusion, wound healing and vascular diseases for which he has received expenses for travel, accommodation and sundries. TR is a director of The Iron Clinic Ltd and director of Veincare London Ltd. TR is also the vascular lead for 18-Week Wait Ltd. Shannon Farmer reports personal fees from Thieme Stuttgart, Germany, and Elsevier Science USA, non-financial support from the National Blood Authority (Australia), the Medical Society for Blood Management and non-financial support from The Health Round Table, outside the submitted work. Dr. Hofmann reports personal fees from Vifor Pharma AG and TEM International GmbH, outside the submitted work. The other authors declare no conflict of interest.